RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Celyad Oncology Stock

Celyad Oncology ROCE 2025

Celyad Oncology ROCE

-11.49

Ticker

CYAD.BR

ISIN

BE0974260896

WKN

A1W7Q9

In 2025, Celyad Oncology's return on capital employed (ROCE) was -11.49, a 658.76% increase from the -1.51 ROCE in the previous year.

Celyad Oncology Aktienanalyse

What does Celyad Oncology do?

Celyad Oncology is a biotech company specializing in the discovery and development of new cancer immunotherapies. The company, headquartered in Mont-Saint-Guibert, Belgium, was founded in 2007 and has been listed on the NASDAQ and Euronext stock exchanges since September 2015. The history of Celyad Oncology began with the discovery of CAR-T therapy, which is based on the tumor cell recognition by T cells of the body's immune system. In 2001, researchers at the University of Leuven (Belgium) introduced a new method for culturing T cells, which was a major step in the development of CAR-T therapy. In 2004, the researchers founded Celyad with the aim of developing clinically effective CAR-T therapies. In 2015, the company was renamed Celyad Oncology to emphasize its strategic focus on oncology products. Celyad Oncology has developed a unique business model that focuses on the clinical development of CAR-T cell therapies. The company uses innovative technologies such as allogeneic CAR-T cells, which come from donor tissue from persons other than the patient. These cells have the advantage of being able to be produced in unlimited quantities, enabling the rapid and cost-effective manufacturing of CAR-T cells. In addition, the company has developed a platform technology called "shRNA" that regulates gene expression in T cells, thereby improving the safety and efficacy of CAR-T therapies. The company is divided into various divisions, from preclinical research to the clinical development and commercialization of CAR-T therapies. Celyad Oncology has several product candidates in various stages of development, focusing on indications such as multiple myeloma, acute myeloid leukemia (AML), and solid tumors. One of Celyad Oncology's most promising product candidates is CYAD-01, a CAR-T cell product targeting the CD19 protein. It is currently in a Phase I/IIa clinical trial evaluating the safety and efficacy of CYAD-01 in patients with refractory or relapsed CD19+ B-cell lymphoma. In October 2020, the product candidate achieved a complete response in a patient with a different indication, acute myeloid leukemia (AML). Another product candidate is CYAD-101, an allogeneic CAR-T cell product targeting the NKG2D protein. This protein is overexpressed on many cancer cells but not on healthy cells. CYAD-101 is currently in a Phase I/II clinical trial for the treatment of various tumor types, including lung cancer and pancreatic cancer. Celyad Oncology also collaborates with other companies to further develop its technologies and product candidates. In 2018, the company entered into a partnership with Novartis to utilize Celyad Oncology's CAR-T platform technology for the development of products for solid tumors. In 2019, Celyad Oncology announced a partnership with ONO Pharmaceutical to accelerate the development of CYAD-211, an allogeneic CAR-T cell product for the treatment of multiple myeloma. In summary, Celyad Oncology has not only a unique business model but also promising product candidates and technologies that have the potential to revolutionize the treatment of cancer. With a strong pipeline and targeted clinical development, Celyad Oncology is well positioned to continue its success in the future. Celyad Oncology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Celyad Oncology's Return on Capital Employed (ROCE)

Celyad Oncology's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Celyad Oncology's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Celyad Oncology's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Celyad Oncology’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Celyad Oncology stock

What is the ROCE (Return on Capital Employed) of Celyad Oncology this year?

The ROCE of Celyad Oncology is -11.49 undefined this year.

How has the ROCE (Return on Capital Employed) of Celyad Oncology developed compared to the previous year?

The ROCE of Celyad Oncology has increased by 658.76% increased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Celyad Oncology?

A high Return on Capital Employed (ROCE) indicates that Celyad Oncology has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Celyad Oncology?

A low ROCE (Return on Capital Employed) can indicate that Celyad Oncology has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Celyad Oncology impact the company?

An increase in the ROCE of Celyad Oncology can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Celyad Oncology affect the company?

A decrease in ROCE of Celyad Oncology can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Celyad Oncology?

Some factors that can affect Celyad Oncology's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Celyad Oncology so important for investors?

The ROCE of Celyad Oncology is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Celyad Oncology take to improve the ROCE?

To improve the ROCE, Celyad Oncology can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Celyad Oncology pay?

Over the past 12 months, Celyad Oncology paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Celyad Oncology is expected to pay a dividend of 0 EUR.

What is the dividend yield of Celyad Oncology?

The current dividend yield of Celyad Oncology is .

When does Celyad Oncology pay dividends?

Celyad Oncology pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Celyad Oncology?

Celyad Oncology paid dividends every year for the past 0 years.

What is the dividend of Celyad Oncology?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Celyad Oncology located?

Celyad Oncology is assigned to the 'Health' sector.

Wann musste ich die Aktien von Celyad Oncology kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Celyad Oncology from 4/22/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 4/22/2025.

When did Celyad Oncology pay the last dividend?

The last dividend was paid out on 4/22/2025.

What was the dividend of Celyad Oncology in the year 2024?

In the year 2024, Celyad Oncology distributed 0 EUR as dividends.

In which currency does Celyad Oncology pay out the dividend?

The dividends of Celyad Oncology are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Celyad Oncology

Our stock analysis for Celyad Oncology Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Celyad Oncology Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.